ABSTRACT
Objectives: This study aimed to observe the change of arachidonic acid-induced platelet aggregation rate (AA-Ag) and short-term adverse reactions after taking 50 or 100 mg/d aspirin(enteric-coated sustained-release formulation) or 100 mg/d aspirin (enteric-coated aspirin tablet)in the elderly Chinese population (aged 60 years or older). Methods: A total of 1 194 participants aged 60 or older, who should be recommended to take aspirin therapy due to medical reasons, were recruited and randomly assigned into three groups to receive enteric-coated sustained-release aspirin tablet (50 mg, once daily, group A), or 100 mg, once daily (group B) or enteric-coated aspirin tablet 100 mg once daily (group C), respectively. AA-Ag was measured after (14±3)days of aspirin treatment. Adverse events and bleeding events were recorded during the (28±3)days of follow-up. Results: The AA-Ag in group A (n=347), B (n=338) and C (n=332) post 14-day aspirin therapy were 6.65 (4.03,10.84)%, 5.89(3.22,10.03) % and 6.00(3.68,10.09) %, respectively (P>0.05). During the 28 days follow-up, the adverse events rate of group A (n=388), B (n=387) and C (n=385) was 3.87%,3.36%, and 7.95%, and the mild bleeding events rate was 3.09%, 2.33%, and 6.23%, respectively. Adverse events rate and mild bleeding events rate were significantly higher in group C than in group A and B (P<0.05). Conclusions: Compared with 100 mg-dose aspirin, 50 mg-dose aspirin achieves similar anti-platelet aggregation effect in this elderly Chinese population. The short-term adverse events and mild bleeding risk of aspirin with enteric-coated sustained-release formulation were fewer than that of enteric-coated formulation.
ABSTRACT
BACKGROUND: Three-dimensional (3D) bioprinting technology has a huge potential in the tissue engineering field, which is expected to create simple tissue/organ analogues with good biological histocompatibility and biological functions by using living cells and biomaterials. OBJECTIVE: To analyze the characteristics of 3D bioprinting technology and all kinds of biomaterials, and to explore its application in the preparation of tissues/organs analogues. METHODS: Relevant articles published from 1998 to 2017 were searched in PubMed, Web of Science, MEDLINE, and WanFang databases. The keywords were "3D bioprinting, 3D bioprinting technology, biomaterial, tissue engineering" in English and Chinese, respectively. A total of 88 articles were initially searched and 47 eligible articles were finally reviewed in accordance with the inclusion and exclusion criteria. RESULTS AND CONCLUSION: 3D bioprinting techniques mainly include inkjet technique (thermal inkjet and piezoelectric inkjet), pressure-assisted technique, laser-assisted technique, and stereolithography technique (single-photon-based and two-photon-based). The bio-ink consists of living cells, natural polymers and synthetic polymers. 3D bioprinting has exhibited a huge potential in the manufacture of living cell-containing tissue/organ analogues. Despite the fact that it has been widely studied, currently used 3D bioprinting techniques can only be used to prepare relatively simple structures with simple biological functions. Research on the specific tissue/organ analogues with living cells are still in its infancy.